11.00-14.00Workshop A: Improving Solubility and Stability
70-90% of new compounds are poorly soluble, how can we address this critical problem in pharmaceuticals? Work closely with the Head of Preformulation at Lundbeck, Rene Holm, to discuss how por solubility can be overcome. Learn, share experiences and discuss the best practice approaches to improving solubility and stability of new compounds and drug candidates. Rene will be discussing key issues such as:
- How can poor solubility be overcome- what crucial compound modifications can be made?
- Can the use of nano particles solve the solubility problem
- What techniques and technologies are available to improve oral bioavailability?
Chair:
Rene Holm
Head of Preformulation
Lundbeck
Dr. Holm brings over 10 years experience working with Lundbeck across pharmaceutical development and preformulation. He is (co-) author of more than 30 original articles in peer-reviewed journals in the field of biopharmaceuticals and preformulation and is names as (co-) author of 5 patents within the same field.
14.30-17.30 Workshop B: Mitigating Late Stage Development Risk by Predicting In Vivo Performance: In Vitro In Vivo Correlation
- Making the connection between in vitro and vivo performance: what models, tools and techniques can be used?
- Assessing the key hurdles in effectively predicting in vivo performance, can we develop some best practice approaches?
- Working through real life case studies to demonstrate how successful in vivo performance has been predicted and what methods and technologies were used along the way
Chair:
Professor Jean Michelle Cardot
Head of Department of Biopharmaceutics and Pharmaceutical Technology
Universite d’Auvergne
J-M. Cardot brings over 20 years experiences working in the pharmaceutical industry and as a professor and now Department Head at Auvergne University, France.
He is pharmacist (D Pharm), and got his Masters in Biopharmaceutical, Statistical Sciences and Pharmacokinetics and has a Ph. D. from Clermont-Ferrand University. His research fields are Biopharmaceutical development of drugs, in vivo bioequivalence and in vitro-in vivo correlation.